TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02985710

Intervention type: DEVICE
Group type: OTHER
Intervention: Sudoscan
Description: The Sudoscan is a non invasive procedure and similar to standing on a scale to be weighed. Sudoscan measurements are made in compliance with the manufacturer's recommended procedures. The measurement is rapid and non-invasive, and requires no advance preparation.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sudoscan
Description: The Sudoscan is a non invasive procedure and similar to standing on a scale to be weighed. Sudoscan measurements are made in compliance with the manufacturer's recommended procedures. The measurement is rapid and non-invasive, and requires no advance preparation.
Study: NCT00550628

Intervention type: OTHER
Intervention: diagnostic laboratory biomarker analysis

Intervention type: OTHER
Intervention: immunoenzyme technique

Intervention type: OTHER
Intervention: immunohistochemistry staining method

Intervention type: PROCEDURE
Intervention: biopsy

Intervention type: PROCEDURE
Intervention: therapeutic conventional surgery

Intervention type: RADIATION
Intervention: fludeoxyglucose F 18
Study: NCT01887834

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Kyodophilus multi-strain probiotic capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Kyodophilus Matching Placebo Capsules
Study: NCT02459171

Intervention type: OTHER
Intervention: Questionnaire
Description: Once at enrollment, subjects will complete an enrollment question to capture poultry exposure and other demographic information. Information will be updated if needed at annual follow-up and at final visits.

Intervention type: OTHER
Intervention: Blood sample
Description: Participants will have a 3-mo blood sample drawn for serological testing at enrollment, and at annual follow-up and final visits.~For subjects who test positive for influenza A by rapid test or PCR (index case) on nasal swab at the biweekly or weekly visits, two 3-ml blood samples will be obtained from the index case on day 1 for serological testing for antibodies against avian influenza viruses and for isolating and studying PBMCs. Blood samples will also be obtained on day 1 from all household contacts of the index case. Additional 3-ml blood samples will be obtained on day 14 for serology and PBMCs.

Intervention type: OTHER
Intervention: Nasal wash
Description: Nasal washes will be obtained from subjects who test positive for influenza A by rapid test or PCR on nasal swab (index case). Nasal washes will also be obtained from all household contacts of the index case. The index case and household contacts will be re-sampled on days 3, 6, 9 and 14 post initial diagnosis date.

Intervention type: OTHER
Intervention: Throat swab
Description: Throat swabs will be obtained from subjects who test positive for influenza A by rapid test or PCR on nasal swab (index case). Throat swabs will also be obtained from all household contacts of the index case. The index case and household contacts will be re-sampled on days 3, 6, 9 and 14 post initial diagnosis date.
Study: NCT02985710

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Skin biopsy
Description: For subjects that give additional consent, skin biopsy will be done in standard fashion under sterile conditions. Assessment of nerve fiber density typically involves a 3-mm punch biopsy of skin from the leg (10 cm above the external malleolus).
Study: NCT03984526

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: intravenous normal saline pretreatment at the onset of dexmedetomidine infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atropine 0.5mg
Description: intravenous atropine 0.5mg pretreatment at the onset of dexmedetomidine infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ephedrine 8mg
Description: intravenous ephedrine 8mg pretreatment at the onset of dexmedetomidine infusion
Study: NCT04359966

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg, Clarithromycin 500 mg, Metronidazole 400 mg,
Description: First line therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40mg, Bismuth subcitrate 120 mg, Amoxicillin 500 mg, Metronidazole 400 mg
Description: First line therapy second arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg, Bismuth subcitrate 120 mg, Amoxicillin 500 mg, Metronidazole 400 mg
Description: Second line therapy for Helicobacter pylori infection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40mg, Amoxicillin 500 mg, Levofloxacin 500 mg
Description: Second line therapy for Helicobacter pylori infection second arm
Study: NCT04163783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-BGB-3111
Description: 20-mg capsule containing \~200 μCi of \[14C\]-BGB-3111,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-3111
Description: Three 20-mg capsules of BGB-3111 and three 80-mg capsules of BGB-3111
Study: NCT01826669

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Patients submitted to respiratory muscle stretching related to the increase thoracic mobility. Stretching were performed in the upper trapezius, scalenes, sternocleidomastoids, major pectoral and intercostals. The muscle stretching were performed passively by a single therapist trained and experienced. The subjects were positioned supine or lateral, knees flexed in order to correct the lumbar curve. Stretching occurred during the expiratory phase, leading to muscle maximum length, with two series of ten consecutive incursions for each muscle, with an interval of one minute between series. The patients were properly informed to perform slow exhalations and pursed-lip during stretching.
Study: NCT02818634

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Harvesting rib cartilage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Harvesting rib cartilage
Study: NCT00643539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zithromax
Description: azithromycin (Zithromax) pediatric suspension formulation (200 mg/5 ml) administered as an oral suspension at a dose of 20 mg/kg once a day (maximal dose 500 mg/day) for 3 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clamoxyl
Description: Amoxicillin (Clamoxyl) pediatric formulation (500 mg/5 ml) administered as an oral suspension at a dose of 25 mg/kg twice daily (maximal dose 2 g/day) for 6 consecutive days
Study: NCT04558008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online MBSR
Description: Described previously
Study: NCT00745030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozerem
Description: Subjects take 1 8mg tablet 30 minutes before bedtime everyday for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 8 mg tablets
Study: NCT02759822

Intervention type: PROCEDURE
Intervention: Haploidentical Stem Cell Transplantation
Description: Haploidentical Stem Cell Transplantation from a related donor (partially matched sibling, father, mother, son or daughter).

Intervention type: PROCEDURE
Intervention: Haploidentical Stem Cell Transplantation
Description: Haploidentical Stem Cell Transplantation from a related donor (partially matched sibling, father, mother, son or daughter).
Study: NCT01089725

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: 1 ml of placebo administered SC and IV once every 8 weeks.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: 1 ml of placebo administered SC and IV once every 8 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab SC
Description: 1 ml tanezumab injection SC administered every 8 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo IV
Description: 1 ml placebo administered IV every 8 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab SC
Description: 1 ml tanezumab injection SC administered every 8 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo IV
Description: 1ml placebo administered IV every 8 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab SC
Description: 1 ml tanezumab injection SC administered every 8 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo IV
Description: 1ml placebo administered IV every 8 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab IV
Description: 1 ml tanezumab injection IV administered every 8 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo SC
Description: 1ml placebo administered SC every 8 weeks
Study: NCT01725412

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Thiamine 300mg PO once daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00258843

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliomyelitis vaccine
Description: 0.5 mL, intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliomyelitis vaccine
Description: 0.5 mL, IM
Study: NCT03963375

Intervention type: DRUG
Group type: OTHER
Intervention: Cladribine
Description: All participants will receive cladribine 10 mg tablets at a cumulative dosage of 3.5 mg/kg divided into 2 treatment courses as per the United States Prescribing Information (USPI) (1.75 mg/kg per treatment course; Year 1 and Year 2 treatment). Patients will be randomized 1:2:2:1 to receive a total of 2 Lumbar Punctures at specific time points during the treatment cycle.

Intervention type: DRUG
Group type: OTHER
Intervention: Cladribine
Description: All participants will receive cladribine 10 mg tablets at a cumulative dosage of 3.5 mg/kg divided into 2 treatment courses as per the United States Prescribing Information (USPI) (1.75 mg/kg per treatment course; Year 1 and Year 2 treatment). Patients will be randomized 1:2:2:1 to receive a total of 2 Lumbar Punctures at specific time points during the treatment cycle.

Intervention type: DRUG
Group type: OTHER
Intervention: Cladribine
Description: All participants will receive cladribine 10 mg tablets at a cumulative dosage of 3.5 mg/kg divided into 2 treatment courses as per the United States Prescribing Information (USPI) (1.75 mg/kg per treatment course; Year 1 and Year 2 treatment). Patients will be randomized 1:2:2:1 to receive a total of 2 Lumbar Punctures at specific time points during the treatment cycle.

Intervention type: DRUG
Group type: OTHER
Intervention: Cladribine
Description: All participants will receive cladribine 10 mg tablets at a cumulative dosage of 3.5 mg/kg divided into 2 treatment courses as per the United States Prescribing Information (USPI) (1.75 mg/kg per treatment course; Year 1 and Year 2 treatment). Patients will be randomized 1:2:2:1 to receive a total of 2 Lumbar Punctures at specific time points during the treatment cycle.
Study: NCT06043284

Intervention type: DEVICE
Intervention: Hyperbaric Oxygen Therapy
Description: Subjects received 100% medical grade oxygen for 60 minutes at 2.0 ATA for 40 sessions in a hard-sided monoplace hyperbaric chamber
Study: NCT02238171

Intervention type: DRUG
Intervention: Atrovent® inhalets
Study: NCT01215864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCD-717
Description: Patients will receive TCD-717 at the following dose levels:~2, 4, 7, 10, 14, 19, 25, 31, 39, 49 or 61 mg/m\^2
Study: NCT01166243

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrin Pad
Description: Fibrin Pad is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care is a composite of techniques/methods typically used by the surgeon to control bleeding.
Study: NCT03160859

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Unsedated colonoscopy with water exchange (WE) where the residual air in the colon will be removed and water will be infused to guide insertion through an airless lumen. Infused water is removed predominantly during insertion.

Intervention type: DEVICE
Group type: OTHER
Intervention: Study method
Description: Unsedated colonoscopy with water exchange (WE + cap) and the addition of a cap fitted to the colonoscope.
Study: NCT02985710

Intervention type: PROCEDURE
Group type: OTHER
Intervention: QSART
Description: QSRT (quantitative sudomotor axon reflex test) testing involves having a technician wipe the subject's arms and leg with alcohol, then tissue to wipe it dry. Electrodes filled with acetylcholine are put on three areas of the leg and one on the wrist, stimulators are turned on and sweat responses are measured.
Study: NCT02590510

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: The quantity of methotrexate is different in the two groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: The quantity of methotrexate is different in the two groups.
Study: NCT03532490

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast 500 Mcg Oral Tablet
Description: The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day.
Study: NCT00635180

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: isometric exercise
Study: NCT01960478

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: (for each intervention)
Study: NCT05713058

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control diet
Description: 12-week dietary prescription with moderate energy restriction (approximately 200 kcal/day) without any recommendations on the distribution of macronutrients within the day
Study: NCT01018862

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelastine hydrochloride nasal spray 0.15%
Description: 822 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
Study: NCT01960478

Intervention type: OTHER
Group type: OTHER
Intervention: Blood test
Study: NCT03383939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A
Description: one nebulization with 250mg alpha-1-antitrypsine diluted in 10ml injectable solution once a day during 1 month. A CR-60 high flow compressor and Ventstream nebulizer were used for nebulization.
Study: NCT01018862

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelastine hydrochloride nasal spray 0.10%
Description: 548 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
Study: NCT03383939

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group B
Description: 10ml of 0.9% NaCl saline solution nebulised once daily for 1 month. A CR-60 high flow compressor and Ventstream nebulizer were used for nebulization.
Study: NCT00539344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANG1005
Description: IV infusion once every 21 days
Study: NCT01018862

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
Study: NCT04221113

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy
Description: Two protocols have been described for physiotherapy of post extensor tendon injuries. one is immobilization till 3 weeks and than gradual increase in active motion of hand. The second protocol is early active motion. this would be done under senior physiotherapist.
Study: NCT00884065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diacutaneous Fibrolysis
Description: The implementation of the technique consists of three consecutive stages: The first stage involves manual palpation, which is carried out by the hand that is not holding the hook, with the objective to find the area to be treated; the second, or instrumental palpation stage, is carried out by introducing the spatula of the hook together with the index finger of the palpatory hand to locate with precision the adherent connective fibers or fibrous corpuscles; the third, or fibrolysis stage, is the actual treatment. Here, a brief supplementary traction is carried out with the hook.
Study: NCT00798512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Description: The MO.MA is a cerebral protection catheter based on the proximal flow blockage concept which is achieved by endovascular clamping of Common Carotid Artery (CCA) and External Carotid Artery (ECA). The MO.MA proximal flow blockage cerebral protection device is indicated to be used in patients eligible for carotid angioplasty and/or the carotid bifurcation and is aimed to prevent brain embolism during the stenting procedure.~For the purpose of this study the Cristallo Ideale™ Carotid Stent System (Invatec S.R.L. Roncadelle, Italy) will be exclusively used. Cristallo Ideale™ consists of a carotid dedicated self-expanding stent pre-mounted on a rapid exchange delivery catheter. The stent platform is made of a Nitinol alloy and characterized by a hybrid design with closed cell in the central zone and open cell in both end zones (proximal and distal).
Study: NCT01056107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ROSE-010
Description: The study medication was used in 30 mcg, 100 mcg, and 300 mcg subcutaneous injections daily, depending upon study arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ROSE-010
Description: The study medication was used in 30 mcg, 100 mcg, and 300 mcg subcutaneous injections daily, depending upon study arm.
Study: NCT01056107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ROSE-010
Description: The study medication was used in 30 mcg, 100 mcg, and 300 mcg subcutaneous injections daily, depending upon study arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection daily
Study: NCT03858582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: pembrolizumab 200mg
Study: NCT00429416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-leucyl-L-leucine Methyl Ester (LLME)
Description: Infusion of L-leucyl-L-leucine methyl ester (LLME) treated donor white blood cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2 prior to HSCT infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 2gm/m2 prior to HSCT infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 1gm/m2 prior to HSCT infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus given before and after HSCT infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna 1gm/m2/day given prior to HSCT infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)
Description: GM-CSF given post HSCT infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation (HSCT)
Description: CD34 selected allogeneic stem cell infusion with 5x104/kg untreated T cells
Study: NCT03156816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine group (experimental arm)
Description: In the experimental group, patients will receive colchicine, starting with a loading dose of 2 mg at the time of revascularization and continuing with 0.5 mg twice daily (b.i.d) for 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group (control arm)
Description: In the placebo group, patients will receive placebo, starting with a loading dose of 2 mg at the time of revascularization and continuing with 0.5 mg twice daily for 5 days.
Study: NCT00884065

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diacutaneous Fibrolysis (placebo)
Description: The placebo was designed for this study and the stages of manual and instrumental palpation occur strictly at a superficial level. In the third stage, instead of fibrolysis a pinch of skin is hold with the thumb of the palpatory hand and the tip of the spatula, so that the patient feels the hook distinctly but without any action taking place on the deep tissular planes.
Study: NCT03540940

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP
Description: 7cmH2O positive end expiratory pressure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ZEEP
Description: 0 cmH2O positive end expiratory pressure
Study: NCT03858582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: pembrolizumab 200mg

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 52.8Gy/24Fx or 59.4Gy/27Fx
Study: NCT04624997

Intervention type: OTHER
Intervention: biological sample
Description: biological sample
Study: NCT04102644

Intervention type: OTHER
Intervention: Observation
Description: Documentation of course and outcome of hospitalization, labor, delivery, and postpartum period
Study: NCT01507727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tablet;15mg/tab; 30mg/tab; 15/30/60mg/day for 7 days Plus conventional therapy according to each patient's underlying disease, such as CHF, hepatic cirrhosis and SIADH or others.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo plus conventional therapy according to each patient's underlying disease, such as CHF, hepatic cirrhosis and SIADH or others.
Study: NCT01574404

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Polar body biopsy with PGS
Description: PB biopsy and analysis by comparing the PB results to the FISH/microarray results
Study: NCT00589368

Intervention type: BEHAVIORAL
Intervention: Transfer of grasp control across hands
Description: transfer of planning and execution of grasp across hands in terms of its effect on fingertip forces, and the timing and magnitude of muscle contraction in patients with hemiparesis and healthy controls

Intervention type: BEHAVIORAL
Intervention: Transfer of grasp control across hands
Description: transfer of planning and execution of grasp across hands in terms of its effect on fingertip forces, and the timing and magnitude of muscle contraction in patients with hemiparesis and healthy controls
Study: NCT02585492

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Head-of-bed elevated 15°
Description: Head-of-bed elevated 15° during 2 hours after delivery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head-of-bed elevated 45°
Description: Head-of-bed elevated 45° during 2 hours after delivery.
Study: NCT00669331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled mannitol
Description: 400mg dose of Mannitol BD (twice a day) for 52 weeks
Study: NCT01096329

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Spray 5% and 1%
Description: Testosterone Spray 5% 2x90uL for 14 days Testosterone Spray 1% 2x90uL for 14 days